Skip to main content

Keros Therapeutics, Inc.

corporate_fare Company Profile

Keros Therapeutics, Inc.

KROS·NASDAQ·Life Sciences·CIK 0001664710

We are a clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. We specialize in understanding the role of TGF-ß proteins, which regulate the growth, repair, and maintenance of tissues such as skeletal muscle, bone, adipose, heart tissue, and blood. Using this knowledge, we have discovered and are developing protein therapeutics. Our lead product candidate, rinvatercept (KER-065), is being developed for neuromuscular diseases. Rinvatercept is designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A, which negatively regulate muscle and bone mass and strength. We are developing rinvatercept for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). In March 2025, we announced initial topline results from the Phase 1 clinical trial of rinvatercept in healthy adult volunteers. Our most advanced product candidate, elritercept (KER-050), is being developed for low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc. (Takeda) to further develop, manufacture, and commercialize elritercept worldwide outside of mainland China, Hong Kong, and Macau. This agreement became effective on January 16, 2025.

Keros Therapeutics, Inc. (NASDAQ:KROS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for KROS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for KROS spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • Keros Posts 70-Cent Quarterly EPS as Shares Sit Near 52-Week Low
  • Keros to Receive $20M Takeda Milestone for ELRiSE MF Trial, Plans 25% Stockholder Distribution
  • Keros Doses First Patient in Phase 2 DMD Trial of Rinvatercept
  • Keros Therapeutics Reports Q2 Loss, Secures $20M Takeda Milestone, CFO Transition Confirmed
  • Keros Therapeutics Posts Q2 2026 Loss of $1.45/Share, Extends Cash Runway into 2028, and Launches Phase 2 DMD Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$243.86M
Net Income
$87.01M
Diluted EPS
$2.30
Op. Cash Flow
$107.5M
Free Cash Flow
$105.95M
Operating Income
$67.57M
Cash & Equivalents
$287.42M
Debt / Equity
0.00×
Net Margin
35.7%
Shares Outstanding
19.54M sh
Source: 10-K · filed 2026-03-04 · accession 0001664710-26-000018

Short Interest & Short Volume

7.06 days to cover

FINRA reported short interest of 1,086,309 shares in KROS as of the October 30, 2026 settlement, a 4.4% decrease from the prior period — about 7.1 days to cover at its recent average daily volume. On November 20, 2026, 34.0% of KROS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,086,309 shares as of October 30, 2026
Change vs prior period▼ 4.4%
Days to cover7.06 at avg daily volume of 153,862
Daily short volume (FINRA facilities)34.0% of 67,607 shares on November 20, 2026
5-day average short volume30.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for KROS, detected from its recent SEC filings · based on capital-structure filings through 2026-09-10.

ATM program1 shelf registration

$350M Universal Shelf Registration · $100M ATM Program Restored

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with K →
$11.08
52-week range · as of 2026-09-29 $9.69 – $22.55
Market cap
$217.44M
Volume
208.7K (1.0× avg)
3-mo avg 210.8K
Live data · 2026-11-22 09:32 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KROS - Latest Insights

KROS
Nov 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.45
Real-time Price: $11.08 info
Change: +$1.63 (+17%) info
Market Cap: $217.438M info
KROS
Sep 29, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.35
Real-time Price: $11.08 info
Change: -$0.270 (-2%) info
Market Cap: $217.438M info
KROS
Sep 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.70
Real-time Price: $11.08 info
Change: -$0.620 (-5%) info
Market Cap: $217.438M info
KROS
Aug 03, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.02
Real-time Price: $11.08 info
Change: +$1.06 (+11%) info
Market Cap: $217.438M info
KROS
Aug 03, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.02
Real-time Price: $11.08 info
Change: +$1.06 (+11%) info
Market Cap: $217.438M info
KROS
Aug 03, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.11
Real-time Price: $11.08 info
Change: +$0.970 (+10%) info
Market Cap: $217.438M info
KROS
Jul 30, 2026, 6:54 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.31
Real-time Price: $11.08 info
Change: +$0.7661 (+7%) info
Market Cap: $217.438M info
KROS
Jul 30, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.37
Real-time Price: $11.08 info
Change: +$0.710 (+7%) info
Market Cap: $217.438M info
KROS
Jul 22, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.21
Real-time Price: $11.08 info
Change: +$0.870 (+9%) info
Market Cap: $217.438M info
KROS
Jun 25, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.41
Real-time Price: $11.08 info
Change: +$0.670 (+6%) info
Market Cap: $217.438M info
KROS
May 14, 2026, 8:02 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.86
Real-time Price: $11.08 info
Change: -$0.780 (-7%) info
Market Cap: $217.438M info
KROS
May 14, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.86
Real-time Price: $11.08 info
Change: -$0.780 (-7%) info
Market Cap: $217.438M info
KROS
May 14, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.65
Real-time Price: $11.08 info
Change: -$0.570 (-5%) info
Market Cap: $217.438M info
KROS
Mar 09, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $11.08 info
Change: -$0.070 (-0.63%) info
Market Cap: $217.438M info
KROS
Mar 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.08 info
Change: -$2.27 (-17%) info
Market Cap: $217.438M info
KROS
Mar 04, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
9
Price at Filing: $13.77
Real-time Price: $11.08 info
Change: -$2.69 (-20%) info
Market Cap: $217.438M info
KROS
Mar 04, 2026, 4:04 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $13.35
Real-time Price: $11.08 info
Change: -$2.27 (-17%) info
Market Cap: $217.438M info
KROS
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.03
Real-time Price: $11.08 info
Change: -$3.95 (-26%) info
Market Cap: $217.438M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets